| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
119,920,000 |
| Market
Cap: |
2.59(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$14.96 - $32.96 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Denali Therapeutics is a biopharmaceutical company that discovers and develops therapeutics to defeat neurodegenerative diseases. Co.'s clinical-stage programs are: leucine-rich repeat kinase 2 inhibitor program to address Parkinson's disease; enzyme transport vehicle :IDS program, its lead brain-penetrant enzyme replacement therapy, enabled by its enzyme transport vehicle, which is designed to restore iduronate 2-sulfatase, and reduce glycosaminoglycans, both peripherally and in the brain, in patients with mucopolysaccharidosis II; and eukaryotic initiation factor 2 B activator program to address diseases such as amyotrophic lateral sclerosis and frontotemporal dementia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
98,964 |
196,455 |
253,657 |
527,733 |
| Total Sell Value |
$2,026,023 |
$3,848,138 |
$5,326,320 |
$13,514,934 |
| Total People Sold |
3 |
6 |
6 |
7 |
| Total Sell Transactions |
5 |
20 |
39 |
77 |
| End Date |
2024-03-14 |
2023-12-12 |
2023-06-13 |
2022-06-13 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ho Carole |
Chief Medical Officer |
• – – |
2020-08-21 |
4 |
D |
$32.88 |
$64,248 |
D/D |
(1,954) |
6,511 |
|
- |
|
| Krognes Steve E. |
CFO and Treasurer |
• – – |
2020-08-21 |
4 |
D |
$32.87 |
$64,228 |
I/I |
(1,954) |
1,006,511 |
|
- |
|
| Schuth Alexander O. |
COO and Secretary |
• – – |
2020-08-20 |
4 |
OE |
$0.00 |
$0 |
I/I |
5,643 |
616,516 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2020-08-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,643 |
8,465 |
|
- |
|
| Krognes Steve E. |
CFO and Treasurer |
• – – |
2020-08-20 |
4 |
OE |
$0.00 |
$0 |
I/I |
5,643 |
1,008,465 |
|
- |
|
| Crestline Management, Lp |
10% Owner |
– – • |
2020-08-12 |
4 |
S |
$31.65 |
$45,678,768 |
I/I |
(1,443,247) |
12,201,634 |
|
-194% |
|
| Bratton Capital Inc. |
10% Owner |
– – • |
2020-06-30 |
4 |
S |
$24.01 |
$1,088,601 |
I/I |
(45,345) |
448,035 |
|
-148% |
|
| Bratton Capital Inc. |
10% Owner |
– – • |
2020-06-29 |
4 |
S |
$23.84 |
$1,982,373 |
I/I |
(82,578) |
493,380 |
|
-135% |
|
| Bratton Capital Inc. |
10% Owner |
– – • |
2020-06-26 |
4 |
S |
$23.84 |
$2,922,078 |
I/I |
(122,077) |
575,958 |
|
-128% |
|
| Bratton Capital Inc. |
10% Owner |
– – • |
2020-06-23 |
4 |
S |
$25.69 |
$515,969 |
I/I |
(20,024) |
698,035 |
|
-75% |
|
| Bratton Capital Inc. |
10% Owner |
– – • |
2020-06-22 |
4 |
S |
$24.66 |
$2,231,902 |
I/I |
(90,056) |
718,059 |
|
-76% |
|
| Bratton Capital Inc. |
10% Owner |
– – • |
2020-06-19 |
4 |
S |
$24.20 |
$3,556,503 |
I/I |
(144,920) |
808,115 |
|
-81% |
|
| Watts Ryan J. |
President and CEO |
• • – |
2020-06-18 |
4 |
GD |
$0.00 |
$0 |
I/I |
40,000 |
2,389,304 |
|
- |
|
| Tessier-Lavigne Marc |
Director |
– • – |
2020-06-16 |
4 |
S |
$26.10 |
$10,440,000 |
D/D |
(400,000) |
2,739,043 |
|
-72% |
|
| Crestline Management, Lp |
10% Owner |
– – • |
2020-06-05 |
4 |
S |
$25.75 |
$49,513,516 |
I/I |
(1,922,855) |
13,644,881 |
|
-70% |
|
| Watts Ryan J. |
President and CEO |
• • – |
2020-03-30 |
4 |
S |
$19.48 |
$93,640 |
D/D |
(4,807) |
22,013 |
|
-64% |
|
| Krognes Steve E. |
CFO and Treasurer |
• – – |
2020-03-30 |
4 |
S |
$19.48 |
$27,817 |
D/D |
(1,428) |
1,006,488 |
|
-64% |
|
| Schuth Alexander O. |
COO and Secretary |
• – – |
2020-03-30 |
4 |
S |
$19.49 |
$27,812 |
D/D |
(1,427) |
28,662 |
|
-64% |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2020-03-30 |
4 |
S |
$19.48 |
$27,817 |
D/D |
(1,428) |
2,822 |
|
-64% |
|
| Crestline Management, Lp |
10% Owner |
– – • |
2020-02-26 |
4 |
S |
$20.25 |
$78,868,971 |
I/I |
(3,894,764) |
15,567,736 |
|
-17% |
|
| Watts Ryan J. |
President and CEO |
• • – |
2020-02-08 |
4/A |
OE |
$0.00 |
$0 |
D/D |
14,315 |
26,820 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2020-02-07 |
4/A |
OE |
$0.00 |
$0 |
D/D |
4,250 |
4,250 |
|
- |
|
| Schuth Alexander O. |
COO and Secretary |
• – – |
2020-02-07 |
4/A |
OE |
$0.00 |
$0 |
D/D |
4,250 |
30,089 |
|
- |
|
| Krognes Steve E. |
CFO and Treasurer |
• – – |
2020-02-07 |
4/A |
OE |
$0.00 |
$0 |
D/D |
4,250 |
1,007,916 |
|
- |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2019-12-23 |
4 |
AS |
$20.01 |
$69,315 |
D/D |
(3,464) |
0 |
|
- |
|
427 Records found
|
|
Page 11 of 18 |
|
|
0.58 (2.76%) 
